The Latest Breaking News from Obesity

Dear Eli Lilly Stock Fans, Mark October 29 on Your Calendar

Eli Lilly’s weight-loss boom faces fierce competition, but its next earnings report could reveal why the best may still be ahead.

Barchart · 10h ago

Understanding the Labrador: Why This Breed Is Every Indian Family's First Choice

Walk into almost any apartment complex in Bengaluru, Noida, or Pune on a Sunday morning and you will find a Labrador, usually pulling its owner toward the nearest dog it can greet. India's most-kept pedigree dog did not earn that position by accident. The Lab is genuinely good at living…

Times Pets · 15h ago

Indian Spitz: why the dog of the 1980s Indian home is back in demand

Walk through any old family photo album from a 1980s Indian home and there is a reasonable chance a fluffy white dog sits in the frame. Not a Pomeranian, not a Samoyed, an Indian Spitz, grinning at the camera like it owns the house. For two decades it was the…

Times Pets · Oct 24

5 Fatty Liver Subtypes Could Change How Doctors Assess Risk

Two people can receive the same fatty liver diagnosis but face very different health risks. One may have a relatively mild condition, while another could be more vulnerable to serious liver damage, heart disease or other complications. Scientists at Mayo Clinic have now identified five biologically distinct subtypes of metabolic…

MyLifeXP · Oct 21

Started a GLP-1 drug like Ozempic or Mounjaro? Here’s what you need to know about nutrition

Around half a million Australians use GLP-1 medications for diabetes – and when you add people who use it for obesity and weight-related conditions, the total is much higher.

The Conversation · Oct 20

GLP-1 Users with Sleep Apnea Had About 40% Lower Acute Respiratory Failure Risk in Early CHEST Data

Sleep apnea patients on GLP-1 drugs had less acute respiratory failure in a nearly 2-million-patient CHEST 2026 analysis. What the data can't show.

Medical Daily · Oct 19

Would subsidising weight loss drugs make health care fairer?

GLP-1 medicines such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity, but access to them in Australia increasingly depends on something much less medical: whether you can afford them.

The Conversation · Oct 19

FSSAI proposes banning addition of fructose, sucrose in baby food products

The FSSAI has drafted an amendment to restrict the use of sucrose and fructose in infant food products aimed at infants below six months. This initiative is designed to elevate nutritional standards and minimize sugar intake in early childhood, directly relating to public health concerns like rising childhood obesity. Feedback…

The Economic Times · Oct 17

Women with PCOS Are Trying GLP-1 Drugs to Get Pregnant, but Fertility Evidence Is Still Early and Limited

Some women with PCOS hope GLP-1 drugs will help them conceive. Here is what early studies show, when to stop the drugs, and what to ask a doctor first.

Medical Daily · Oct 16

Roche Bets Up to $1.16 Billion on Rona's Obesity Drug That Aims to Cut Fat but Spare Muscle

Roche licensed Rona's experimental ALK7 obesity drug in a deal worth up to $1.16 billion. No human data are out yet. What it means for weight loss.

Medical Daily · Oct 15